Trial Profile
A Randomized, Multicenter, Phase II Study of Docetaxel and TS-1 Combination as a First-Line Treatment in Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2011
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- 25 Jul 2011 Planned end date changed from 1 Jun 2012 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 25 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Dec 2008 New trial record.